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ABSTRACT
The new genetic engineering technique CRISPR-Cas9 projects benefits 
and risks of genetically manipulating and altering living organisms in 
order to bring about characteristics that are favorable to themselves and 
to humans. With an interdisciplinary method, involving Philosophy, Law, 
Biosafety and Bioethics, this paper aims to verify the consequences that 
the use of this technique can bring to the genetic nature of organisms, 
especially from the ethical and legal points of view. As a legal and 
biosafety reference, we opted for Brazilian Law n. 11.105/2005 and for 
philosophical and bioethical reference, we approach the controversy 
between the German thinkers Jürgen Habermas and Peter Sloterdijk, who 
analyzed the subject of genetic engineering and the risk of eugenics. It is a 
theoretical-bibliographic research, which uses deductive reasoning on the 
legal-philosophical impacts of the CRISPR-Cas9 technique. The practice 
of genetic engineering, despite the risks, may be an inevitable procedure 
in the present stage of human development and confronting it with an 
understanding of legal and bioethical responsibilities becomes essential.
Keywords: CRISPR-Cas9; genetic manipulation; genetic engineering; 
biosafety; bioethics.
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CRISPR-CAS9, BIOSSEGURANÇA E BIOÉTICA: UMA ANÁLISE 
JUSFILOSÓFICA-AMBIENTAL DA ENGENHARIA GENÉTICA
 
RESUMO
A nova técnica de engenharia genética CRISPR-Cas9 projeta benefícios 
e riscos de se manipular e alterar geneticamente organismos vivos, de 
forma a trazer características favoráveis a eles mesmos e aos seres 
humanos. Com abordagem interdisciplinar, envolvendo a Filosofia, o 
Direito, a Biossegurança e a Bioética, o artigo objetiva verificar quais 
as consequências que o uso da referida técnica pode trazer à natureza 
genética dos organismos, sobretudo dos pontos de vista ético e jurídico. 
Como referência jurídica e de Biossegurança, optou-se pela Lei brasileira 
n. 11.105/2005 e, como referência filosófica e bioética, abordou-se a 
controvérsia entre os pensadores alemães Jürgen Habermas e Peter 
Sloterdijk, que analisaram o tema da engenharia genética e do risco 
da eugenia. Trata-se de pesquisa teórico-bibliográfica, que emprega o 
raciocínio dedutivo sobre os impactos jurídicos-filosóficos do uso da 
técnica do CRISPR-Cas9. A prática da engenharia genética, apesar 
dos riscos, pode ser um procedimento inevitável diante do atual estágio 
de desenvolvimento humano e enfrentá-la com a compreensão das 
responsabilidades jurídica e bioética torna-se essencial.
Palavras-chave: CRISPR-Cas9; manipulação genética; engenharia 
genética; biossegurança; bioética.
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INTRODUCTION
 
Genetic manipulation has always been shrouded in bioethical 
and legal polemics. However, in recent years a new genetic engineering 
technique has promised to revolutionize the expensive genetic alteration 
processes.
The CRISPR-Cas9 technique allows the replacement of 
fragments of the DNA chain, correcting genetic “failures” or inserting 
beneficial characters into a given organism.
The possibility of having control over the genome and the genetic 
characteristics of the organisms raises the reflection on the risks of a nature 
projected for human interests and also the risks of eugenic practices when 
these changes are turned to the human genome.
The present research presents an interdisciplinary study, 
involving Philosophy, Law, Biosafety and Bioethics in order to verify 
how the CRISPR-Cas9 technique can affect what we know as the genetic 
nature of living organisms, facing the raised ethical and legal problems. 
The Biosafety juridic reference will be Brazilian Law n.11.105/2005, 
which addresses the issues of genetic engineering and manipulation, both 
in human cells and other living organisms.
To reflect from a philosophical and bioethical perspective, the 
article uses the controversy between the German thinkers Jürgen Habermas 
and Peter Sloterdijk, who analyzed the subject of genetic engineering and 
the risk of eugenics.
It is, therefore, a theoretical-bibliographic research, which 
employs the deductive reasoning of the legal-philosophical impacts on the 
use of the CRISPR-Cas9 technique. 
To do so, it begins with an exposition of the CRISPR-Cas9 
technique, in its biological and biotechnological aspects.
Next, it addresses the legal treatment of Biosafety in Brazil. 
After contextualizing Biosafety and its development, some provisions 
of Law n.11.105/2005 are analyzed, aiming to give an overview of its 
legal treatment, emphasizing the rules regarding genetic engineering and 
manipulation.
Finally, the CRISPR-Cas9 technique is confronted with gene 
therapy through adenovirus or retroviruses and an exposition is made 
regarding the risks of these techniques compared to Bioethics.
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1 CRISPR-CAS9: AN ANALYSIS
CRISPR is an acronym for the English term Clustered Regularly 
Interspaced Short Palindromic Repeats. The first time a CRISPR sequence 
was identified was in a study on the Escherichia coli bacteria in 1987, 
although it was not yet understood under such name (ISHINO et al., 1987). 
Japanese researchers noticed in certain DNA sequences pieces of genes 
that did not belong naturally to the genome of Escherichia coli. In the 
early 2000s, the Spanish researcher Francisco Mojica (2000) identified 
CRISPR in other different species, such as archaea and other unicellular 
microorganisms.
The role of CRISPR will then be associated with a natural 
defense capacity of bacteria and archaea against viruses (MAKAROVA 
et al., 2006), which would justify that the genes which are not part of the 
genome of the studied organisms would be adaptations resulting from the 
viruses’ attacks:
 
[...] bacteria and archaea would have sophisticated immune systems. After all, viruses 
are the most abundant biological agents on the planet, causing roughly infections 
every second. The selective pressures imposed by viral predation have resulted 
in the evolution of numerous phage defense systems, but it was only recently that 
sophisticated adaptive defense systems were identified in both bacteria and archaea 
(ERP et al., 2015, p. 85). 
 
Such a hypothesis will be proven in 2007 by scientists of 
American, French and Canadian origin who worked for Danisco, a Danish 
food company. Researchers have started from the notion that many bacteria 
are used for fermentation and biotechnological processes of food, but that 
such bacteria are attacked by phages, which are often not neutralized by 
the usual processes (BARRANGOU et al., 2007). 
The researchers studied a milk-fermenting bacteria for the 
production of foods such as yogurt and cheese called Streptococcus 
thermophilus. They did an experiment with bacteria and two bacteriophages 
that had already been isolated by the yogurt industry. Nine more phages 
were generated from the experiment between the previously bacteria and 
two phages. Subsequently, the bacterium was immune to the new phages 
and the authors questioned the reason. When comparing the DNAs of 
the bacteria and the new phages, the authors stated that the resistance of 
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Streptococcus thermophilus was due to the fact that CRISPR in the DNA 
of the bacteria had adapted to the DNA of the phages: “These results 
reveal that, on becoming resistant to bacteriophages, the CRISPR locus 
was modified by the integration of novel spacers, apparently derived from 
phage DNA.” (BARRANGOU et al., 2007, p. 1710). 
In other words:
 
[...] CRISPR functioned like a molecular vaccination card: by storing memories of 
past phage infections in the form of spacer DNA sequences buried within the repeat-
spacer arrays, bacteria could use this information to recognize and destroy those 
same invading phages during future infections (DOUDNA, STERNBERG, 2017, 
p. 56). 
 
The bacteria, therefore, would have an ability to remember the 
viruses that have already infected it, from the DNA of those viruses, which 
would be incorporated into the CRISPRs of the bacteria. When the bacteria 
were attacked again by the viruses, they were resistant. 
Studies on bacteria would be just the beginning of the CRISPR 
analysis. From then on, a number of articles were devoted to it, although 
not understanding how the whole procedure involved occurred. It was 
already known, however, that the process for bacterial resistance depended 
on the actuation of RNA guiding molecules. One study found that RNA 
would be responsible for coordinating the recognition and destruction of 
viral infections, and that this would involve the CRISPR defense system. 
RNA molecules were produced by cells, through CRISPR, to fight the 
DNA sequences of the invading virus (BROUNS et al., 2008). In short,
 
CRISPR loci are transcribed, and the long primary transcript is processed into 
a library of short CRISPR-derived RNAs (crRNAs) that each contain a sequence 
complementary to a previously encountered invading nucleic acid. Each crRNAs is 
packaged into a large surveillance complex that patrols the intracellular environment 
and mediates the detection and destruction of foreign nucleic acid targets 
(WIEDENHEFT; STERNBERG; DOUDNA, 2012, p. 331). 
 
In addition to CRISPR and the participation of RNA in its 
performance, the attention of researchers should also focus on Cas genes, 
which is present in the region of the genomes of the bacteria and which 
contains special types of proteins called enzymes, which function as 
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catalysts of molecular reactions in cells. Thus, by understanding the role of 
Cas protein in this process, they could understand how CRISPR actually 
works (DOUDNA, STERNBERG, 2017, p. 62).
Blake Wiedenheft, a researcher working with Jennifer Doudna, 
one of those who came to discover CRISPR’s ability to “cut” any kind 
of gene, was able to separate numerous Cas proteins in one experiment 
(DOUDNA, STERNBERG, 2017, p. 63-64). In possession of these Cas 
proteins, Wiedenheft et al. (2009) found a protein enzyme Cas1, with 
the ability to cut DNA, which would suggest that the protein had a role 
along the process of constitution of the defense system and adaptation 
of organisms’ DNAs to viruses’ attacks. Other Cas proteins were being 
manipulated and discovered. Finally, it can be elucidated that bacterial 
defense systems had several types of Cas proteins, which had the function 
of “searching” and “cutting” (“cleaving”) the viral DNAs, preventing their 
action. It was thus discovered the operation of the defense system that 
involves CRISPR. Initially, the CRISPR RNA (crRNA) molecule, which 
has ten or eleven different Cas proteins, acts in the conservation against the 
attacks of virus DNAs by localizing them. Next, the Cas proteins enzymes 
act by “cutting” the target DNA (DOUDNA, STERNBERG, 2017, p.63; 
66). Such a process inactivates the virus genes and prevents them from 
acting. 
Among the Cas proteins studied, the one that caused the greatest 
impact was Cas9 (which will be known as part of the CRISPR type II 
system1). Jennifer Doudna and Emmanuelle Charpentier led a team that 
discovered the unique role of Cas9:
 
They had independently been teasing out the roles of various CRISPR-associated 
proteins to learn how bacteria deploy the DNA spacers in their immune defenses. 
But the duo soon joined forces to focus on a CRISPR system that relies on a protein 
called Cas9, as it was simpler than other CRISPR systems. 
When CRISPR goes into action in response to an invading phage, bactéria transcribe 
1 On a technical explanation regarding the types of CRISPR/Cas systems: “There are three types of 
CRISPR/Cas systems (21–23)The type I and III systems share some overarching features: specialized 
Cas endonucleases process the pre-crRNAs, and once mature, each crRNA assembles into a large 
multi-Cas protein complex capable of recognizing and cleaving nucleic acids complementary to the 
crRNA. In contrast, type II systems process pre-crRNAs by a different mechanism in which a trans-ac-
tivating crRNA (tracrRNA) complementary to the repeat sequences in pre-crRNA triggers processing 
by the double-stranded (ds) RNA-specific ribonuclease RNase III in the presence of the Cas9 (formerly 
Csn1) protein (fig. S1) (4, 24). Cas9 is thought to be the sole protein responsible for crRNA-guided 
silencing of foreign DNA (25–27).” (JINEK et al., 2012, p. 16). 
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the spacers and the palindromic DNA into a long RNA molecule that the cell then 
cuts into short spacer-derived RNAs called crRNAs. An additional stretch of RNA, 
called tracrRNA, works with Cas9 to produce the crRNA [...] (PENNISI, 2013, p. 
834). 
 
The discoveries so far have occurred on the natural level. The 
big question that emerged then is whether the researchers themselves 
could take advantage of Cas9 to manipulate and manually cut out other 
DNA sequences: “What we wanted to do next was confirm that we could 
engineer Cas9 and the RNA molecules to target and cut any DNA sequence 
of our choice.” (DOUDNA, STERNBERG, 2017, p.81). 
 
Illustrations on the CRISPR-CAS9 method: Left - DNA cut; Right - DNA Manipulation. Credits: 
Renato Serra 
 
Jennifer Doudna, Emmanuelle Charpentier and the team decided 
to do an experiment to prove the hypotheses raised regarding CRISPR-
Cas9. They decided to use genes from a jellyfish for the experiment. 
Researcher Martin Jinek made the process manually of CRISPR and Cas9. 
He chose five different gene sequences and “chimerically” prepared five 
RNA molecules to combine them. He then incubated the RNA with Cas9 
and the jellyfish DNA and waited for the result. He checked, then, that 
jellyfish DNA was cut off. The RNA molecules had acted in the exact place 
where the researcher had selected for the “cut”, occurring through Cas9. A 
new technology capable of editing any genome in any organism was then 
validated and constructed! (DOUDNA; STERNBERG, 2017, p. 82-83). 
Without properly describing the reported research, the news regarding the 
CRISPR/Cas9 manipulation was mentioned in an article of the same group 
of scientists, published in August 2012:
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Our study further demonstrates that the Cas9 endonuclease family can be programmed 
with single RNA molecules to cleave specific DNA sites, thereby raising the exciting 
possibility of developing a simple and versatile RNA-directed system to generate 
dsDNA breaks for genome targeting and editing (JINEK et al., 2012, p. 816).
 
Such a study would trigger a series of research involving 
CRISPR and its potentialities. Several articles would study the genetic 
editing of different cell types. In addition to the dairy industry, which 
already benefited from the incipient applications of CRISPR, several other 
areas would benefit from the technique, such as agribusiness, other food 
areas, biotechnology and the medical field2. The reason for the progress of 
research with CRISPR involved the ability of genetic manipulation, but 
also the ease of manipulation and the low cost: “But the real reason that 
CRISPR exploded onto the biotech scene with such force and vitality was 
its low cost and ease of use. CRISPR finally made gene editing available 
to all scientists.” (DOUDNA; STERNBERG, 2017, p. 111). Another 
factor that has contributed to the CRISPR revolution is the advancement of 
computational technology:
 
Computers have also made gene editing easier than ever before. Using advanced 
algorithms that incorporate all the relevant design principles, including empirical data 
from the scientific literature on what kinds of targeting sequences work better than 
others, various software packages offer researchers an automated, one-step method 
to build the best version of CRISPR to edit a given gene (DOUDNA; STERNBERG, 
2017, p. 112).
 
Progress has continued. In May 2013, Wang et al. (2013) 
conducted an experiment with CRISPR that would also open up many 
possibilities for what is perhaps one of the great dilemmas the method 
would have to face: the manipulation of germ cells and embryos. In addition 
to the first embryonic cell edition, the research was able to do several 
manipulations simultaneously. And although the employed technique 
manipulated an embryo, it opened up the possibility that CRISPR could 
be used on egg cells and sperm, which would allow genetic transmission 
for later generations: “[...] it seemed that CRISPR could be injected into 
any species’ germ cells (eggs and sperm) or embryos, and the resulting 
genetic changes would be faithfully copied into all the cells and forever 
2 For information regarding the entry of the CRISPR technique in the market Cf. ERP et al., 2015.
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transmitted to future offspring” (DOUDNA; STERNBERG, 2017, p. 98).
Even before the CRISPR technique was officially used in the 
edition of human embryos in the United States, several scientists signed a 
manifesto called Don’t edit the human germ line, in which they pleaded to 
their peers not to develop such research before a serious debate on ethics was 
raised. The text draws attention to the fact that until that moment, in March 
2015, several researches that used the CRISPR technique were already 
being done with other animals, which would be a step towards research 
on human germ cells (ovum and sperm): “Studies using gene-editing in 
animals such as rats, cattle, sheep and pigs, indicate that it is possible to 
delete or disable genes in an embryo — a simpler process than actually 
correcting DNA sequences — in only some of the cells” (LAMPHIER et 
al., 2015, p. 411). Manipulations with human germ cells had already been 
done with other techniques, but with CRISPR, the changes could be passed 
on to later generations. Due to possible risks, many countries that have the 
technical capacity to make genetic manipulations in germ cells refer to 
legal norms to prohibit the changes:
 
Many countries do not have explicit legislation in place permitting or forbidding 
genetic engineering in humans — considering such research experimental and not 
therapeutic (see go.nature.com/uvthmu). However, in nations with policies regarding 
inheritable genetic modification, it has been prohibited by law or by measures having 
the force of law. This consensus is most visible in western Europe, where 15 of 
22 nations prohibit the modification of the germ line. Although the United States 
has not officially prohibited germline modification, the US National Institutes of 
Health’s Recombinant DNA Advisory Committee explicitly states that it “will not 
at present entertain proposals for germ line alterations” (see go.nature.com/mgscb2) 
(LAMPHIER et al., 2015, p. 411). 
 
The fact that a tougher legislation exists in Western European 
countries opens up a greater possibility of genetic manipulation at germ 
level with the CRISPR technique to occur in other countries, as will be 
seen later. 
The Lamphier et al. (2015) manifest is explicit in stating that the 
greatest fear is regarding eugenic practice and possible harm to our own 
human lineage, so a public debate with specialists, scholars, and public 
opinion is essential to raise the discussion on whether and under what 
circumstances the germ-level manipulation technique in humans should 
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occur, which would not imply, however, in excluding all research involving 
genetic manipulation. 
On October 28, 2016 the CRISPR-Cas9 technique was first 
tested on a human. A Chinese team, led by oncologist Lu You of Sichuan 
University in Chengdu, has modified cells using the CRISPR technique 
to fight lung cancer in a patient. The procedure consisted in the removal 
of immune cells from the patient’s blood, which were manipulated with 
CRISPR-Cas9. Thus, a specific gene, which has the function of encoding 
the PD-1 protein, has been deactivated (cut). Such a protein eventually 
impairs the immune response of cells, causing the proliferation of cancers. 
The edited cells were cultured and their numbers increased. Subsequently, 
they were injected back into the patient. The team’s hope is that edited cells 
without PD-1 will attack cancer (CIRANOSKI, 2016).
The treatment described above was against cancer, however, it 
should be emphasized that the CRISPR-Cas9 method has been applied to 
the study of several diseases, by the fact that it can revert mutations or 
exchange a damaged gene for healthy ones, although there are diseases 
that, for the time being, are not potentially treated by CRISPR-Cas9:
 
Beyond cancer, HIV, and the genetic disorders discussed thus far, a quick survey of 
the published scientific literature reveals a growing list of diseases for which potential 
genetic cures have been developed with CRISPR: achondroplasia (dwarfism), chronic 
granulomatous disease, Alzheimer’s disease, congenital hearing loss, amyotrophic 
lateral sclerosis (ALS), high cholesterol, diabetes, Tay-Sachs, skin disorders, fragile 
X syndrome, and even infertility. [...] There are all sorts of disorders — from autism 
to heart disease — that don’t show significant genetic causation or are caused by a 
complex combination of genetic variants and environmental factors. In these cases, 
gene editing may be of more limited use (DOUDNA; STERNBERG, 2017, p. 181-
182).
 
The gains from CRISPR-Cas9 and the real impact of his technique 
contributed to the US National Academies of Sciences, Engineering, 
and Medicine (2017) making a report called Human Genome Editing: 
science, ethics, and governance3 in which they take a favorable position 
on genetic manipulation in embryos and germ cells, provided they follow 
some guidelines. The committee’s conclusions can be summarized in the 
following principles and concluding observations:
 
3 The report contains 310 pages and brings many issues that could be analyzed in detail. It was decided, 
purposely, to emphasize certain aspects that were relevant for this paper .
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Genome editing holds great promise for preventing, ameliorating, or eliminating 
many human diseases and conditions. Along with this promise comes the need for 
ethically responsible research and clinical use.
RECOMMENDATION 2-1. The following principles should undergird the oversight 
systems, the research on, and the clinical uses of human genome editing:
1. Promoting well-being
2. Transparency
3. Due care
4. Responsible science
5. Respect for persons
6. Fairness
7. Transnational cooperation (NATIONAL..., 2017, p. 182)
 
These principles, in turn, will result in responsibility for editing 
the human genome. The following explains each of the listed principles 
and their respective responsibilities linked.
1. Promotion of welfare: one should always seek the benefit 
(principle of beneficence) and prevention of harm (principle of non-
maleficence) of those involved in the research  The responsibilities are: 
a) to use the human genome edition for treatments or prevention of diseases 
and does not apply it in cases of great uncertainty; b) seek the benefits also 
bearing in mind the risks involved.
2. Transparency: Information should be given to stakeholders 
in a clear and comprehensible manner  The responsibilities are: a) 
commitment to exposing the greatest amount of information in a quickly 
manner; b) submit information for the construction of public policies.
3. Due caution: care should be taken with those involved, acting 
only on the basis of strong evidence.  The responsibility is: to act with 
caution and frequent reassessment of actions, also taking cultural opinions 
into account.
4. Responsible science: one should act based only on high 
standards of research, following the guidelines of international and 
professional norms. The responsibilities are: a) to conduct high-level 
research; b) review and evaluate researches following the protocols; c) be 
transparent; d) correct misinformation.
5. Respect for persons: the dignity of all individuals should 
be acknowledged, respecting their particular decisions, and taking 
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all individuals with the same moral value, regardless of their genetic 
properties.  The responsibilities are: a) to have the same commitment 
to all; b) respect for decisions; c) prevent eugenic practices, such as those 
already practiced; d) destigmatize deficiencies.
6. Equity: treat similar cases in the same way and practice 
distributive justice in relation to risks and benefits. The responsibilities 
are: a) to distribute research tasks and benefits; b) provide universal and 
equitable access to the benefits of the investigations. 
7. Transnational cooperation: there must be international 
research collaboration, taking into account the different cultural contexts. 
Responsibilities are: a) to respect the different national policies; b) seek 
common standards; c) share data achieved. 
The report probably encouraged embryo research to be conducted 
in the United States using the CRISPR-Cas9 technique. A few months later, 
this was confirmed by an investigation involving researchers of different 
nationalities and led by Shoukhrat Mitalipov, a researcher at Oregon Health 
and Science University in Portland. It was the first experiment with embryos 
in the United States, funded by private sectors, since the US government 
does not fund jobs involving human embryos (LEDFORD, 2017). The 
authors used the CRISPR-Cas9 technique to rectify a disease-generating 
mutation in embryos. The study consisted of working the mutation of a gene 
called MYBPC3, which generates hypertrophic cardiomyopathy, a disease 
that results in heart failure and is the most common cause of sudden death 
in young and healthy athletes. The rate of manipulated embryos that did 
not have the mutant gene was high (MA, 2017)4. The pioneering American 
ground-based research put the country into a silent dispute with China for 
embryonic research using the CRISPR-Cas9 technique. 
In the middle of 2018, the CRISPR-Cas9 method received two 
heavy setbacks: on the one hand, two texts (HAAPANIEMI et al., 2018; 
IHRY et al., 2018) showed evidence that genetic editing with CRISPR-
Cas9 favors the appearance of tumors, on the other, a study (KOSICKI; 
TOMBERG; BRADLEY, 2018) emphasized that CRISPR-Cas9 may 
cause more genetic destruction than the experts thought. Although they are 
not studies that definitely put the technique in check, they warn of possible 
collateral damage that should be further investigated. 
In the first case, despite investigating different types of cells, 
4 The results of the experiment, which would be due to the CRISPR-Cas9 technique, were later ques-
tioned by EGLI, Dieter et al. (2018). However, for the purposes of analysis, the most important is the 
manipulation of embryos in the United States on the experiment cited above.
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human retinal pigment epithelial cells (HAAPANIEMI et al., 2018) and 
human pluripotent stem cells (hPSCs) (IHRY et al., 2018), researchers 
noticed that the DNA cut with CRISPR-Cas9 activates a gene called p53, 
which has the function of dealing with the damage caused by the cut: “Here, 
we report that genome editing by CRISPR-Cas9 induces a p53-mediated 
DNA damage response [...]” (HAAPANIEMI et al., 2018, p. 927). It is as 
if the body tried to readjust after the cut, often causing CRISPR not to have 
the expected effectiveness: “The toxic response to DSBs5 was P53/TP53-
dependent, such that the efficiency of precise genome engineering in hPSCs 
with a wild-type p53 gene was severely reduced” (IHRY et al., 2018, p. 
939). That is, the effect of CRISPR would depend on the non-performance 
of the p53 gene. “These results suggest that p53 inhibition may improve the 
efficiency of genome editing of untransformed cells and that p53 function 
should be monitored when developing cell-based therapies utilizing 
CRISPR-Cas9” (HAAPANIEMI et al., 2018, p. 927). But the problem is 
precisely because, when p53 does not act (naturally or induced), the risk 
of cancer increases exponentially, which would in principle suggest a risk 
in the use of the technique: “P53 inhibition could alleviate toxicity but has 
the potential to increase off-target mutations and poses a risk for cancer.” 
(IHRY et al., 2018, p. 945). But, also, a greater control in its application: 
“Controlling DNA damage signaling, such that efficient gene correction 
can occur but the formation and selection of potentially tumorigenic cells 
are suppressed, will be important in developing safer and more efficient 
next generation genome editing technologies.” (HAAPANIEMI et al., 
2018, p. 930). 
The research conducted by Kosicki, Tomber and Bradley (2018), 
in turn, found that the use of CRISPR-Cas9 causes destructive effects at 
different sites where the DNA was cut, destroying other DNAs that were not 
involved in the process, which can cause serious pathogenic consequences, 
including the appearance of genes that cause cancers:
 
In the clinical context of editing many billions of cells, the multitude of different 
mutations generated makes it likely that one or more edited cells in each protocol 
would be endowed with an important pathogenic lesion. Such lesions may constitute 
a first carcinogenic ‘hit’ in stem cells and progenitors, which have a long replicative 
lifespan and may become neoplastic with time (KOSICKI; TOMBERG; BRADLEY, 
2018, p. 770). 
In the view of the authors, there has been a negligence in the 
investigations involving the use of CRISPR-Cas9 in certain cases, since it 
5 From the English “double-strand breaks” of DNA.
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should be further studied:
 
We speculate that current assessments may have missed a substantial proportion of 
potential genotypes generated by on-target Cas9 cutting and repair, some of which 
may have potential pathogenic consequences following somatic editing of large 
populations of mitotically active cells (KOSICKI; TOMBERG; BRADLEY, 2018, 
p. 765).
 
By the end of 2018, an experiment using the CRISPR-Cas9 
technique would cause a riot in the scientific milieu: a Chinese researcher, 
He Jiankui, from Shenzhen, announced that he implanted embryos handled 
with the CRISPR-Cas9 technique, which resulted in the birth of two girls 
which would be the first genetically engineered human born. His research 
consisted of disabling a gene, called CCR5, which allows access to the 
HIV virus in a cell. His justification was to make organisms resistant to 
the disease, very common in China, and that the offspring did not have 
parental disease (he used parents with HIV and mothers without the virus). 
The method consisted of:
 
The gene editing occurred during IVF, or lab dish fertilization. First, sperm was 
“washed” to separate it from semen, the fluid where HIV can lurk. A single sperm 
was placed into a single egg to create an embryo. Then the gene editing tool was 
added.
When the embryos were 3 to 5 days old, a few cells were removed and checked 
for editing. Couples could choose whether to use edited or unedited embryos for 
pregnancy attempts. In all, 16 of 22 embryos were edited, and 11 embryos were used 
in six implant attempts before the twin pregnancy was achieved, He said.
Tests suggest that one twin had both copies of the intended gene altered and the other 
twin had just one altered, with no evidence of harm to other genes, He said. People 
with one copy of the gene can still get HIV, although some very limited research 
suggests their health might decline more slowly once they do (MARCHIONE, 2018).
 
There were serious doubts of the scientific community that the 
research had occurred, since it did not appear in any scientific journal that 
could be analyzed by other researchers. There were also questions about 
how He Jiankui recruited the research participants, since he might not 
have been clear about the method used. Some scientists questioned the 
fact that the edition of the CCR5 gene could also make it possible for other 
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diseases to appear. It was also unclear whether the researcher did the right 
thing in the face of the competent bodies and institutions involved. There 
is also the questioning that there are people whose organism undergoes a 
natural mutation in the CCR5 gene, which makes them immune to HIV 
and that, therefore, the test made is implicitly justifiable by the pure and 
simple application of the technique (MARCHIONE, 2018). And the most 
fundamental question: Would He Jiankui have crossed a risky line, or 
would he have been the pioneer of something inevitable?
The supposed experiment generated a chain reaction. 
Several scientists have criticized the fact that it has been done without 
a consensus in the scientific world about the genetic editing on humans 
and its implantation. In China itself, the author’s country of origin, where 
there is authorization for genetic editing, a group of 122 scientists wrote 
an open letter in which they call He Jiankui crazy and claim that such 
activity was a serious blow to the reputation and scientific development of 
China (KOLATA; WEE; BELLUCK, 2018).A few days later, the Chinese 
government banned He Jiankui from conducting further research. He was 
subsequently detained in an accommodation on the Southern University 
of Science and Technology, in Shenzhen, and was later fired from the 
same university, where he worked. The Chinese authorities, who after an 
investigation confirmed the researcher’s achievements, are likely to take 
harsh measures against him and his staff, framing them on criminal charges 
(RAMZY; WEE, 2019). 
 
2 BIOSECURITY AND BRAZILIAN LAW N. 11.105/2005
 
The incipient experiments involving the CRISPR-Cas9 technique 
raise safety and ethical issues in genetic manipulation procedures.
Certain risks are as yet unknown and Biosafety must act to 
prevent these internal (laboratory) and external (in the release of modified 
organisms) risks.
Biosafety is the set of techniques and procedures that works 
together with research on biological material, seeking the prevention, 
elimination or reduction of risks to human health and the environment, as 
well as maintaining the balance of ecosystems.
In its work with biotechnology, it can be said that Biosafety 
is more pragmatic than Bioethics because it aims to implement safety 
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procedures which should cover activities of investigation, teaching, 
production and distribution of inventions and biotechnological products, as 
well as development and the provision of services related to biotechnology.
Schramm (2010) states that Bioethics can be considered a new 
scope of Moral Philosophy. Its task would be to observe and discuss 
biotechnoscientific advances. Biosafety, in its turn, would be a new field 
of biotechnoscience, concerned with the safety of scientific procedures. 
“In sum, bioethics analyzes the morality of biotechnologies and biosafety 
calculates and weighs the inherent risks of biotechnology from the point of 
view of its safety.” (SCHRAMM, 2010, p. 105).
The earliest landmark of contemporary biosafety is at meetings 
in Asilomar, California, where a series of meetings took place in 1975 
involving leading scientists who discussed ethics in research. The most 
relevant issue at that time was the suggestion of a moratorium on genetic 
research, which occurred in the previous year by a group of scientists.
Through this meeting guidelines were established for the safety 
of experiments with recombinant DNA. Although the term “biosafety” was 
not used at the time, it was the Asilomar document that laid the foundations 
for biosafety.
Today, biosafety procedures are mainly concerned with: 
•	Identify the risks of activities involving the handling of 
biological material;
•	Characterize the risks according to the probability of their 
effects and the extent of their possible consequences;
•	Analyze acceptable levels of exposure to hazardous materials 
or materials with risks as yet unknown;
•	Evaluate the probability of the negative effects of the activity;
•	And in case of damage, evaluate it and propose measures of 
containment and repair.
In Brazil, the main regulatory instrument of Biosafety is Law 
n. 11.105 - Lei de Biossegurança (Biosafety Law) - sanctioned by the 
President of the Republic on March 24, 2005.
As a general matter, the Biosafety Law establishes safety standards 
and inspection mechanisms for construction, cultivation, production, 
handling, transportation, transfer, import, export, storage, research, 
marketing, consumption, release into the environment and disposal of 
genetically modified organisms, with guidelines to stimulate scientific 
advances in the area of biosafety and biotechnology, protection of human, 
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animal and plant life and health, and observance of the precautionary 
principle for the protection of the environment (BRASIL, 2005, art. 1).
The Biosafety Law addresses, as central themes, embryonic 
stem cell research and the research and release of genetically modified 
organisms. However, it also creates restrictions on genetic manipulation.
The Law processing was rough, with pressure from economic 
groups interested in the genetic modification of soy, hitherto deregulated. 
It was during the procedure that the President of the Republic signed 
Provisional Measure n. 223, dated October 14, 2004 - later converted into 
Law n.11.092, of January 12, 2005 -, legalizing the planting of transgenic 
soybean from the 2004-2005 harvest and the commercialization of the 
product until January 31, 2006.
After the promulgation of the Law, another stir has been 
established regarding the research with embryonic stem cells. On May 
30, 2005, the then Attorney General Claudio Fonteles filed a petition 
questioning the constitutionality of Article 5 of the Biosafety Law, which 
allows the use of surplus human embryos of in vitro fertilization techniques 
in research and therapies.
The Attorney General was outraged at the normative treatment 
given to the cryopreserved human embryo, a surplus of in vitro 
fertilization. Its use in research and therapy necessarily implied - at least 
at the time of enactment of the Law and proposition of Direct Action of 
Unconstitutionality - in the destruction of the embryo.
Under the argument that “human life happens in, and from, 
fertilization” Article 5 of the Biosafety Law would offend Article 1, III, 
and the caput of Article 5 of the Federal Constitution. The member of the 
Attorney General’s Office therefore considered human embryos as being 
constitutionally identical to the borne human being, seeking, therefore, 
assistance in the opinions of doctors, geneticists and biologists.
The ADI trial n. 3510-0 began in March 2008, when the Reporting 
Minister Carlos Ayres de Britto and the then President of the Federal 
Supreme Court, Minister Ellen Gracie, voiced on the constitutionality of 
Article 5. The section was suspended due to the request of the Minister 
Carlos Alberto Menezes Direito. Resuming the trial on May 28, 2008, 
Ministers Menezes Direito and Ricardo Lewandowski voted for partial 
submission of the request for unconstitutionality of article 5 of the Biosafety 
Law. Minister Carmen Lúcia Rocha and Minister Joaquim Barbosa deemed 
it unfounded. For its dismissal, Ministers Eros Grau and Cezar Peluso also 
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stated, with certain reservations, in the terms of their votes. The trial was 
adjourned and resumed the next day, May 29, 2008. Taking the votes of the 
other Ministers (Min. Celso Mello, Min. Marco Aurélio and Min. Gilmar 
Mendes) (BRASIL, 2008).
Finally, the Federal Supreme Court, by majority vote and in 
accordance with the vote of the Rapporteur, dismissed the claim in the 
Direct Action of Unconstitutionality n.3.510-0, partially overlapping, in 
different extensions, the Ministers Menezes Direito, Ricardo Lewandowski, 
Eros Grau, Cezar Peluso and Gilmar Mendes, being allowed the research 
with embryonic stem cells, especially from the differentiation of the 
legal treatment given to the unborn child of the one spent to the embryo 
not gestated and frozen as a surplus of techniques of assisted human 
reproduction (BRASIL, 2008).
Research and therapies with human embryos are allowed by the 
Biosafety Law only regarding stem cells, and any technique of genetic 
engineering is prohibited, from which it can be inferred that the CRISPR-
Cas9 technique is also prohibited. The art. 24 criminalizes and punishes 
with imprisonment, from 1 to 3 years, and fine, the conduct of using human 
embryo in disagreement with the provisions of art. 5, that is to say, the use 
of embryos must comply with the following requirements: a) research and 
therapy should have stem cells as object; b) the parents must expressly 
consent to the use; c) prior approval of the research ethics committees 
of the research institutions and health services involved; and (d) is not 
intended for the marketing of biological material (BRASIL, 2005).
On the other hand, the embryo genetic alteration received its 
own classification, being a crime punishable by imprisonment, from 1 to 4 
years, and a fine (BRASIL, 2005, art.25).
Genetic engineering in human germ cell is also prohibited, which 
has been included in the art. 25, with the same punishments related to the 
embryo.
The prohibition of genetic engineering in embryos and human 
germ cells has been inserted with the aim of avoiding possible eugenics, or 
even abusive and invasive practices.
Finally, the Biosafety Law prohibits human cloning, in any of its 
forms, be it reproductive or therapeutic (BRASIL, 2005).
Cloning is the process of asexual reproduction, artificially 
produced, based on a single genetic patrimony, with or without the use of 
genetic engineering techniques. If it is reproductive cloning, the ultimate 
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goal will be to obtain a new individual, genetically the same as the previous 
one. If the cloning is therapeutic, its objective will be the production of 
genetically identical cells that can be used in medical treatment.
Cloning is prohibited through article 26, which provides for 
punishment of 2 to 5 years of imprisonment and a fine for the one who 
performed it (BRASIL, 2005).
 
3 BIOETHICS AND GENE THERAPY
 
In relation to human health, the CRISPR-Cas9 technique opens 
the door to the improvement and expansion of gene therapy, which consists 
in the treatment of diseases, inherited or acquired, in which defective genes 
are manipulated in order to achieve cure or stagnation of the anomaly.
In theory, gene therapy can be performed on somatic cells and 
germ cells, although in the latter the risk is much greater, since the alteration 
of gametes can result in unexpected changes, such as malformations and 
diseases hitherto unknown. There is even the risk of generating recessive 
problems that may only manifest themselves in future generations. 
Before the CRISPR-Cas9 technique, somatic therapy was 
performed by a vector, retrovirus or adenovirus, which inserted new genetic 
material into diseased cells. Viruses act as efficient vectors by having a 
genetic programming that leads them to transfer their genetic material to 
the infected organism. 
Some retroviruses and adenoviruses have ample capacity of 
propagation of their genetic material without destruction of the cells of 
the invaded organism. In somatic therapy, part of the virus’s genome is 
removed, maintaining its reproductive and transfer ability and inserting 
healthy genetic material to be transported. By infecting the patient’s cells, 
the virus transfers the genetic material it is carrying to diseased cells of the 
body, modifying its structure (SÁ; NAVES, 2018).
The CRISPR-Cas9 technique does not use another organism, such 
as the retrovirus or the adenovirus. CRISPR is a DNA sequence that can 
be repeated several times, with unique sequences between the repeats, and 
allows to cut the DNA in specific places. Cas9 is the enzyme responsible 
for this cut. So, through an RNA guiding chain, one piece of the cut DNA 
is removed and replaced with another.
Apparently more effective, the CRISPR-Cas9 technique would 
be more accurate than virus therapy.
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Watson and Berry (2005) report that the first successful gene 
therapy occurred in 1990 at the National Institutes of Health. The patients 
were two children suffering from adenosine deaminase deficiency (ADA), 
Ashanti DeSilva, aged four, and Cindy Cutshall, aged nine. ADA, which 
occurs by the absence of an enzyme, “deactivates” the immune system, 
leaving the patient vulnerable to any disease.
Immune system cells from both girls were harvested and cultured 
in the laboratory, and then infected with retroviruses containing the desired 
genetic material. The retrovirus DNA was transferred to the cells, which 
were reinserted into the patients. Several infusions were made for a few 
months. In parallel to gene therapy, the girls were submitted to enzyme 
replacement, as required by the National Institutes of Health.
Watson and Berry report the results:
 
I can personally attest that Cutshall looked like a very healthy 11-year-old when she 
and her family visited Cold Spring Harbor in 1992.Eleven years later, however, the 
results were not as conclusive. The functioning of DeSilva’s immune system is close 
to normal, but only about a quarter of its T cells came from gene therapy. Cutshall’s 
blood has an even smaller proportion of T cells coming from the therapy, though her 
immune system is also working well. However, it is difficult to say exactly how much 
of this improvement is due to gene therapy and how much is a result of continuous 
enzyme treatment. The result, therefore, is too ambiguous to be interpreted as an 
unequivocal success in gene therapy (Watson, Berry, 2005: 377-378).
 
Some problems can be pointed out in this type of therapy, as the 
case of DeSilva and Cutshall shows. The cells undergoing treatment have a 
short life span, which means that often the healthy genetic material cannot 
reach the whole of the diseased cells. The difficulty in reaching only those 
cells needing the surrogate gene is also clear. In the case of DeSilva and 
Cutshall, the cells to be treated could be obtained easily because they were 
cells of the immune system.
Finally, somatic gene therapy has incalculable oncogenic 
potential. This risk can be inferred from a case that occurred in France in 
2000.At Necker Hospital in Paris, under the leadership of Alain Fischer, 
two babies with ADA underwent therapy. The innovation was due to the 
use of stem cells from the bone marrow of the babies. Thus, when stem 
cells reproduced, they would automatically generate cells with healthy 
genes in a “self-regenerating genetic correction.” (WATSON; BERRY, 
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2005, p. 380).
The results of the therapy were incredible in the early years, but 
in 2002, it was discovered that one of the babies had leukemia. Although 
the oncogenic risk is real, in the case of ADA the result obtained can still 
be considered advantageous, due to its characteristics and difficulties with 
treatments.
These risks presented by virus gene therapy, such as shorter 
cell lifetime and increased oncogenic potential, may also manifest in the 
CRISPR-Cas9 technique, as reported above.
Besides these risks, Habermas (2016) poses important ethical 
issues to be considered in the production of genetically programmed 
humans. There is, with these techniques, a change in the “ethical self-
understanding of the species” that breaks with the existential notion of 
who we are and leads us to a possibility of constructed organic disposition. 
From something given, we become what we give ourselves as an organism.
Moreover, there is a great concern of the German philosopher 
with the self-understanding of the genetically edited person: “We cannot 
rule out the fact that knowledge of a eugenic programming of hereditary 
inheritance limits the autonomous configuration of the individual’s life and 
undermines relations fundamentally symmetric between free and equal 
persons.” (HABERMAS, 2016, p. 33)
Permission to interfere with the genome in search of contribution 
to the health of the person can be seen as beneficial, but the limit that guides 
what is good, preferable or bad is very tenuous. What is really therapeutic 
and what is just desirable?
 
Genetic intervention does not open the communication space to address the planned 
child as a second person and to include it in a process of understanding. [...] The 
eugenic interventions of improvement undermine the ethical freedom as it subjects 
the person in question to intentions set by third parties, which the person rejects 
and are irreversible, preventing them from freely understanding themselves as the 
sole author of their own life. It may be that it is easier to identify with abilities and 
aptitudes than with dispositions or even qualities; but for the psychic resonance of 
the person in question, it only matters the intention that was linked to the purpose 
of the programming. Only if extreme and highly generalized evils are avoided, good 
reasons emerge to accept the fact that the affected individual would agree with the 
eugenic goal (HABERMAS, 2016, p. 86-88).
 Habermas’s position in O futuro da natureza humana (The Future 
of Human Nature) was a response to a writing by the German philosopher 
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Peter Sloterdijk6, which would become the work Regras para o parque 
humano: uma resposta à carta de Heidegger sobre o Humanismo (Rules 
for the Human Zoo: A Response to the Letter on Humanism). Without 
referring properly to the quarrel between the two thinkers, it is important 
to emphasize Sloterdijk’s position on the techno-scientific advance.
For Sloterdijk, the West was marked by humanism, a certain 
formation that would have the capacity to contain human destructive 
instincts: “The latent message of humanism, then, is the taming of men. 
And its hidden thesis is: reading the right books calms the inner beast” 
(SLOTERDIJK, 2009, p. 15). In this sense, there is a belief in humanism 
that humans are influential and that it is fundamental to offer a certain 
kind of control. The bestializing and domesticating tendencies would be 
in constant strife in the human being: “The label of humanism reminds 
us (with apparent innocuousness) of the constant battle for humanity that 
reveals itself as a contest between bestializing and taming tendencies.” 
(SLOTERDIJK, 2009, p. 15). 
In interpreting Heidegger’s Letter on Humanism , written after 
World War II, in 1946, Sloterdijk, based on the Heidegger’s critique that 
humanism (and its derivations, Christianity, Marxism and existentialism) 
is embedded in the metaphysical tradition of the forgetfulness of being, 
perceives the following questioning formulated by Heidegger, which 
calls humanism into question: “Why should humanism and its general 
philosophical self-representation be seen as the solution for humanity, when 
the catastrophe of the present clearly shows that it is man himself, along 
with his systems of metaphysical self-improvement and self-clarification, 
that is the problem?” (SLOTERDIJK, 2009, p. 17). After two great wars, 
made by an educated and humanist Europe, nothing more natural than to 
question the formation that had been based on humanism and its millennial 
conception that the human being is a rationale animal. What interests 
Sloterdijk in his reading of Heidegger is the fact that humanism, as a 
human domestication, has been criticized. What to put, then, in place?
 What can tame man, when the role of humanism as the school for humanity has 
collapsed? What can tame men, when their previous attempts at self-taming have 
6 The Habermas-Sloterdijk debate originated when some journalists published decontextualized sec-
tions of a speech by Sloterdijk (originally presented on June 15, 1997 in the city of Basel, at an event 
on humanism and then resumed in June 1999 at a symposium on Heidegger and Levinas in Elmau and 
that will give rise to the text Regras para o parque humano), implying that the author was in favor of 
eugenic practices.Habermas’s reaction, which will initially take place in the press in a violent manner, 
will result in the work O futuro da natureza humana. In our view, Habermas never really understood 
Sloterdijk’s text.
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led primarily to power struggles? What can tame men, when after all previous 
experiments to grow the species up, it remains unclear what it is to be a grown-up? 
Or is it simply no longer possible to pose the question of the constraint and formation 
of mankind by theories of civilizing and upbringing? (SLOTERDIJK, 2009, p. 20).
 
Following his analysis, Sloterdijk (2009) retakes Nietzsche 
to deduce, from this, that the human being is understood as having a 
domesticating force and a creative force. Socialization ended up producing 
men who are domesticated, but, through their creative force, man will create 
the superman. And it is from this creative force that Sloterdijk, despite 
making exceptions to Nietzsche’s thought, captures the fundamental 
question of our age: the ability, through technique, to literally create “new 
human beings.”
 
But the discourse about difference and the control of taming and breeding – indeed, 
just the suggestion about the decline of awareness of how human beings are produced, 
and indeed of anthropotechnology – these are prospects from which we may not, 
in the present day, avert our eyes, lest they once again be presented as harmless 
(SLOTERDIJK, 2009, p. 23).
 
Sloterdijk, walking on dangerous terrain, which prompts a 
quarrel initiated perhaps by a hasty reading of Habermas, states that the 
history of culture is a history of selection, from literate and illiterate, and 
that there are two types of humans, those who created and those who are 
created, being that the era of the technique perpetuates such division, going 
towards a problematization on the biological level. Humanity will have 
to discuss, as the CRISPR-Cas9 technique demonstrated, the technical 
advances and its capacity to manipulate nature in general and human nature. 
Where humanism has failed to contain destructive impulses, there will be 
technique. And as Sloterdijk says, humanity cannot escape the questions 
about its own self-determination:
 
But whether this process will also eventuate in a genetic reform of the characteristics 
of the species; whether the present anthropotechnology portends an explicit future 
determination of traits; whether human beings as a species can transform birth-
fatalities into optimal births and prenatal selection – these are questions with which, 
however vague and creepy they may be, the evoluntionary horizon begins to glimmer 
(SLOTERDIJK, 2009, p. 24).
CRISPR-CAS9, BIOSAFETY AND BIOETHICS: A JUSPHILOSOPHICAL AND ENVIRONMENTAL ANALYSIS...
146 Veredas do Direito, Belo Horizonte,  v.16  n.34  p.123-152  Janeiro/Abril de 2019
 
Finally, Sloterdijk (2009) turns to Plato and his work O Político, 
in which he finds the notion, in the early days of Western culture, that the 
art of politics is the art of shepherding the city. This is why all Western 
thought has focused on the insidious task of thinking of the human 
community as a zoological park, since the human being is also an animal 
willing voluntarily to be cared for by others, the experts, those who know 
how to unite the best human qualities, an idea that is more than open in 
this biotechnological era and that will inevitably have the CRISPR-Cas9 
technique as one of the exponents. 
Thus, the Bioethics space in this discussion should be expanded 
to allow us to understand that any decision regarding the CRISPR-Cas9 
technique will imply a series of responsibilities with present and future 
generations, and it must not escape its interference in nature and it’s 
consequences.
Global Bioethics is invoked as an important agent of reflection 
in such a thorny subject, since Genetics demands a Bioethics that projects 
itself “into the future leads even to a ‘subject’ who does not exist, does not 
claim and does not have his rights harmed: future generations. Moreover, 
it also addresses other forms of life, since ethics becomes a part of the 
philosophy of nature.” (REIS; NAVES; RIBEIRO, 2018, p. 84)
 
CONCLUSION
 
It cannot be said with absolute certainty that the CRISPR-Cas9 
technique will consolidate itself in the scientific circle. Serious science 
is made gradually by means of tests, counter-tests, experiments and 
discussions. There is, therefore, a long way to go. However, there is no 
denying the potential of the technique. 
CRISPR-Cas9 has the capacity to enter many practical areas 
ranging from food production, animal manipulation, pharmacological 
drugs and finally biotechnology, with emphasis on manipulation in germ 
cells and embryos. Economic, social, political and scientific interests often 
cause the subject to be approached in an exalted manner. 
After presenting the CRISPR-Cas9 technique, from its origin 
until its use in implanted embryos, the article presented elements of the 
Brazilian Biosafety Law. Still, using the debate between the German 
thinkers Habermas and Sloterdijk, the text exposed concerns about the use 
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of CRISPR-Cas9 in eugenic practice, but also raised the hypothesis of an 
unavoidable use of the technique in humans. 
As the technique is usually always at the forefront of ethical-
philosophical reflection and legal positioning, it is extremely necessary that 
both areas (Philosophy and Law) carefully reflect on the explosive potential 
of the CRISPR-Cas9 technique. The virtual change in all aspects of reality 
makes the CRISPR-Cas9 technique clear object of study for Philosophy 
(Environmental), Law (Environmental) and Bioethics (Environmental). 
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